El Salvador
Tuberculosis profile
Population  2013 6.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.061 (0.051–0.072) 0.97 (0.81–1.1)
Mortality (HIV+TB only) 0.033 (0.023–0.044) 0.52 (0.37–0.7)
Prevalence  (includes HIV+TB) 3.1 (1.4–5.4) 48 (22–86)
Incidence  (includes HIV+TB) 2.5 (2.2–2.6) 39 (35–42)
Incidence (HIV+TB only) 0.24 (0.23–0.25) 3.7 (3.6–3.9)
Case detection, all forms (%) 87 (82–97)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.3 (0–1.2) 11 (4.9–20)
MDR-TB cases among notified pulmonary
TB cases
5 (0–21) 14 (6–26)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 424   109
Pulmonary, clinically diagnosed 310   0
Extrapulmonary 333   0
       
Total new and relapse 2 176    
Previously treated, excluding relapses 17    
Total cases notified 2 193    
Among 2 067 new cases:
200 (10%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 205 (14%) 28 (22%) 571
Laboratory-confirmed RR-/MDR-TB cases     14
Patients started on MDR-TB treatment     4
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 142 (98)
HIV-positive TB patients 203 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 162 (80)
HIV-positive TB patients on antiretroviral therapy (ART) 157 (77)
HIV-positive people screened for TB 1 612  
HIV-positive people provided with IPT 1 127  
Treatment success rate (%)
New and relapse cases registered in 2012 93
Previously treated cases, excluding relapse, registered in 2012 60
HIV-positive TB cases, all types, registered in 2012 79
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.2
Culture (per 5 million population) 19.7
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 6.4
% Funded domestically 59%
% Funded internationally 11%
% Unfunded 30%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-05 Data: www.who.int/tb/data